

Table 7: Number of Childhood (Ages 0-19) Brain and CNS Tumors by Major Histology Groupings, Histology, Gender and Race; CBTRUS Statistical Report: NPCR and SEER, 2004-2006

Histology	Total	By Gender		By Race	
		Male	Female	White	Black
<u>Tumors of Neuroepithelial Tissue</u>	7,589	4,065	3,524	6,163	957
Pilocytic astrocytoma	1,834	965	869	1,524	201
Protoplasmic & fibrillary astrocytoma	101	57	44	85	-
Anaplastic astrocytoma	165	81	84	133	21
Unique astrocytoma variants	217	113	104	164	41
Astrocytoma, NOS	497	267	230	397	65
Glioblastoma	297	179	118	222	50
Oligodendroglioma	146	80	66	111	29
Anaplastic oligodendroglioma	39	17	22	-	-
Ependymoma/anaplastic ependymoma	574	296	278	458	74
Ependymoma variants	79	53	26	-	-
Mixed glioma	78	36	42	-	-
Glioma malignant, NOS	1,201	597	604	977	135
Choroid plexus	202	117	85	165	21
Neuroepithelial	30	-	-	-	-
Non-malignant and malignant neuronal/glia	907	506	401	749	119
Pineal parenchymal	92	46	46	56	32
Embryonal/primitive/medulloblastoma	1,130	642	488	935	133
<u>Tumors of Cranial and Spinal Nerves</u>	565	282	283	458	59
Nerve sheath, non-malignant and malignant	565	282	283	458	59
<u>Tumors of Meninges</u>	457	231	226	370	55
Meningioma	285	144	141	222	43
Other mesenchymal, non-malignant and malignant	108	51	57	-	-
Hemangioblastoma	64	36	28	-	-
<u>Lymphomas and Hematopoietic Neoplasms</u>	48	25	23	-	-
<u>Germ Cell Tumors and Cysts</u>	422	297	125	346	39
<u>Tumors of Sellar Region</u>	1,208	410	798	931	161
Pituitary	866	241	625	667	112
Craniopharyngioma	342	169	173	264	49
<u>Local Extensions from Regional Tumors</u>	-	-	-	-	-
<u>Unclassified Tumors</u>	473	247	226	386	55
Hemangioma	105	60	45	90	-
Neoplasm, unspecified	359	184	175	290	49
All other	-	-	-	-	-
TOTAL	10,776	5,564	5,212	8,702	1,336

-Counts are not presented when fewer than 16 cases were reported for the specific histology category. The suppressed cases are included in the counts for totals.

Abbreviation: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, CDC's National Program of Cancer Registries; SEER, NCI's Surveillance, Epidemiology and End Results program